Fecal Calprotectin in Gastrointestinal Disease

Area of Science:

• Gastroenterology
• Clinical Chemistry
• Immunology

Background:

• Inflammatory Bowel Disease (IBD) is a chronic gastrointestinal condition with increasing global incidence.
• Endoscopy is the standard for IBD diagnosis and monitoring, but it is invasive and resource-intensive.
• Fecal calprotectin serves as an accurate non-invasive marker for gastrointestinal inflammation in IBD.

Purpose of the Study:

• To examine preanalytical and analytical factors influencing fecal calprotectin measurements.
• To provide an overview of clinical applications for fecal calprotectin in IBD.
• To highlight the importance of understanding these factors for optimizing clinical care.

Main Methods:

• Review of preanalytical and analytical factors affecting fecal calprotectin assays.
• Examination of current clinical guidelines and research on fecal calprotectin use in IBD.
• Synthesis of information on disease activity assessment, relapse prediction, and therapeutic decision-making.

Main Results:

• Fecal calprotectin aids in assessing IBD activity, predicting relapse, and guiding therapy.
• It can potentially reduce the need for invasive endoscopic procedures.
• Various preanalytical and analytical factors can impact fecal calprotectin results, requiring careful consideration.

Conclusions:

• Fecal calprotectin is a key biomarker in IBD management, offering a non-invasive alternative to endoscopy.
• Understanding and controlling preanalytical and analytical variables are essential for reliable fecal calprotectin testing.
• Optimizing the use of fecal calprotectin can improve patient care and resource allocation in IBD treatment.